Скачать или смотреть Side Effects of Acalabrutinib VS. Ibrutinib in Relapsed CLL - Dr. John Seymour ASH 2021

Bruton tyrosine kinase (BTK) inhibitors like ibrutinib and acalabrutinib are very effective in treating chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL). This study looked at the side effects individuals living with CLL / SLL experience while taking ibrutinib versus acalabrutinib. While both ibrutinib and acalabrutinib are equally effective for controlling CLL and SLL, acalabrutinib is easier to tolerate with fewer side effects.

At the American Society of Hematology (ASH) 2021, CLL Society's own Dr. Brian Koffman interviewed Dr. John Seymour, Director of the Department of Hematology at Peter McCallum Cancer Center in Melbourne, Australia. They discussed updated safety results from a clinical trial comparing acalabrutinib with ibrutinib head-to-head in patients with relapsed/refractory CLL.

Read the full article on CLL Society's website at: https://cllsociety.org/2022/09/ash-20...
__________________________________________________________________________________________
CLL Society Website: https://cllsociety.org/
Facebook:   / cllsociety  
Twitter:   / cllsociety  
LinkedIn:   / cll-society